Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665117 · ClinicalTrials.gov registry record · NA
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT02665117: Completed NA study, sponsored by University of Texas Southwestern Medical Center.
NCT02665117 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02665117, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
Chlorthalidone (CTD) may produce various metabolic disturbances, including hypokalemia, activation of Renin-Angiotensin- Aldosterone (RAA) system, oxidative stress, dyslipidemia, Fibroblast growth factor 23 (FGF23) synthesis, and magnesium depletion. These factors may interact with each other to contribute to the development of insulin resistances and metabolic syndrome. Smaller studies have suggested that Potassium magnesium Citrate (KMgCit) can ameliorate CTD- induced metabolic side effects independent of correction of hypokalemia. This study will tests if KMgCit ameliorates CTD induced metabolic effects independent of correction of hypokalemia.
Primary Outcome
Fasting plasma glucose was measured from venous blood sample at week 4 and week 16
Interventions
- DRUG Chlorthalidone
- DRUG Potassium Magnesium Citrate (KMgCit)
- DRUG Potassium Chloride (KCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-01 |
| Est. Completion | 2022-11-04 |
| Phase | NA |
What the finished NCT02665117 record still lists
NCT02665117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Chlorthalidone is the first listed.
NCT02665117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02665117 about?
NCT02665117 is a clinical study titled "Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate". Chlorthalidone (CTD) may produce various metabolic disturbances, including hypokalemia, activation of Renin-Angiotensin- Aldosterone (RAA) system, oxidative stress, dyslipidemia, Fibroblast growth factor 23 (FGF23) synthesis, and magnesium depletion. These factors may interact with each other to con...
What is the current status of trial NCT02665117?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2015-01. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT02665117?
The interventions under investigation include: Chlorthalidone (DRUG), Potassium Magnesium Citrate (KMgCit) (DRUG), Potassium Chloride (KCl) (DRUG).
Who is sponsoring clinical trial NCT02665117?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02665117's enrollment target sits among peer trials
61 1164th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia